Introduction
Fibroblast growth factor 10 (FGF10) protein deficiency has been reported in patients with bronchopulmonary dysplasia (BPD) [1] . BPD is a chronic lung disease
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Sp3 were found to inhibit Fgf10 transcription in mouse lung explants [4, 5] . The inhibition of Fgf10 expression is mediated by LPS receptors (Toll-like receptor 2 and 4) activation. In the context of the immature lung, the biotrauma and barotrauma induced by inflammation, mechanical ventilation, and oxygen toxicity are known to cause injury [6] [7] [8] [9] . Due to advances in management and therapy, the survival of premature infants has increased. The histological characteristics of BPD have also changed. The 'old' BPD was characterized by emphysema, interstitial fibrosis, and airway squamous metaplasia. The 'new' BPD is thought to be a 'developmental lung disease', arising from arrested alveolar development resulting in hypoalveolization and dysmorphic microvasculature [10] . BPD treatment is a considerable burden on health care systems [11, 12] .
While the evidence confirming the key role of Fgf10 in embryonic lung development is strong [13, 14] , comparatively less is known about the consequences of constitutive Fgf10 insufficiency following lung injury. To demonstrate the effect of Fgf10 deficiency for prenatal and postnatal lung development in normoxic conditions, we used a constitutive heterozygous Fgf10 +/− mouse line. Lung morphometry and gene array were performed to identify changes in the lung structure and global gene expression in Fgf10 +/− versus Fgf10
wild-type (WT) littermate lungs at E18.5. Because oxygen toxicity is one of the major risk factors contributing to BPD, we used the mouse hyperoxia-induced BPD phenocopy model (85% oxygen from P0 to P8) to investigate the impact of Fgf10 deficiency. Surprisingly, all Fgf10 +/− pups died within 8 days of hyperoxic injury. We therefore chose P3, a time point at which there was no observable lethality, to collect pups for further analysis consisting of lung morphometry, gene array, fluorescence-activated cell sorting (FACS), immunofluorescence (IF), reverse transcriptase-quantitative polymerase chain reactions (RT-qPCR), and western blotting. We also used a double transgenic system in mice [15] [16] [17] [18] [19] to attenuate all Fgfr2b ligands postnatally in the context of hyperoxic injury. Our detailed analysis may be critical in designing therapies to prevent lung injury in neonates at risk for BPD and in adult lung disorders characterized by FGF10 deficiency.
Materials and methods

Study approval
Animal studies
All experiments were performed in accordance with the National Institutes of Health Guidelines for the Use of Laboratory Animals. Animal experiments were approved by the Federal Authorities for Animal Research of the Regierungspraesidium Giessen, Hessen, Germany (protocols 105/2011).
Mice
C57BL/6 mice were crossed to generate WT pups.
Fgf10
+/− mice were generated by crossing Fgf10 
Hyperoxia injury (BPD mouse model)
Newborn pups were subjected to hyperoxia (HOX; 85% O 2 ) injury from P0 to P8 in a chamber (ProOx Model 110; BioSpherix, Ltd, Parish, NY, USA). To minimize oxygen toxicity and bias, nursing dams were rotated every 24 h between normoxia (NOX) and HOX. Pups and dams received food and water ad libitum.
Statistical analyses
Significance was determined by two-tailed Student's t-test using GraphPad Prism statistical analysis software (GraphPad, La Jolla, CA, USA). Chi-square analysis (software R, package 'survival') was used for the comparison of survival data of all hyperoxia-exposed litters. All data are presented as mean ± SEM. Values of p < 0.05 were considered significant.
Left lobe perfusion, alveolar morphometry, RNA extraction, RT-qPCR, isolation of primary AECII cells, microarray experiments, FACS, and western blot Details may be found in the supplementary material online, Supplementary materials and methods.
The data from the microarray experiment have been deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE76302 (https://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE76302).
Results
Fgf10 expression is reduced upon hyperoxia (HOX) exposure in neonatal wild-type (WT) lungs
Fgf10 deficiency in a mouse model of BPD 93 Fgf7) that encode Fgf ligands acting via Fgfr2b [21] was assessed by RT-qPCR in the lungs of C57BL/6 WT pups at different time points during normal alveologenesis (between P0 and P35). When normalized to their respective values for the first time point collected (P0), the results indicated a decrease in Fgf10 expression over time, while the genes encoding other Fgfr2b ligands were maintained at stable levels ( Figure 1A, a) . When normalized to Fgf10 expression at each of the considered time-points, Fgf1 and Fgf7 showed higher mRNA levels while Fgf3 was generally present at lower level ( Figure 1A, b) . Comparison of the expression (normalized to the first time point collected, P2) of these ligands' mRNAs in HOX (85% O 2 from P0 onwards) revealed that Fgf10 was the only one with significantly lower levels at P5 and P8 compared with NOX-exposed WT lungs ( Figure 1A, c) .
Fgf10 +/− newborn mice are indistinguishable from WT littermates in NOX, but display increased lethality following HOX injury Considering the previously reported decreased FGF10 expression in human patients with BPD, we investigated whether Fgf10 deficiency in mice could reproduce the clinical complications observed in BPD. We therefore crossed Fgf10 +/− and WT mice and collected embryos at E12.5 (n = 3 and n = 4 for WT and Fgf10 +/− , respectively) and E18.5 (n = 3 and n = 7 for WT and Fgf10 +/− , respectively) and assessed the levels of Fgf10 mRNA in their lungs by RT-qPCR. The relative levels of Fgf10 were 23.7% and 57.9% less at E12.5 (p = 0.04) and E18.5 (p = 0.01), respectively, in Fgf10 +/− versus WT lungs (data not shown). Fgf10 +/− (n = 10) and WT (n = 12) pups exposed to NOX between P0 and P8 ( Figure 1B ) were viable and without phenotypic differences (data not shown). Morphometric analysis of P3 lungs ( Figure 1C , b, d versus a, c; n = 4 for each genotype) showed no significant differences between Fgf10 +/− and WT for the mean linear intercept (MLI), airspace or septal wall thickness ( Figure 1D , a-c). To mimic the BPD phenotype, newborn pups were subjected to HOX for up to 8 days ( Figure 1E ) [22] (see also supplementary material online, Figure S1 for validation of the BPD model). Figure 1E -H displays the results for the pups from two litters combined together (14 pups). Survival analysis showed that all WT mice (n = 8) survived at day 8, while none of the Fgf10 +/− experimental mice (n = 6) were alive at this time point [chi-squared tests on the Cox proportional hazards models (group membership as only predictor): Fgf10 +/− versus WT: chi 2 : 11.6, p < 0.001 (1 degree of freedom, df)]. A 50% lethality was already observed at P5, suggesting that lung damage starts earlier ( Figure 1F ). We therefore analysed WT and Fgf10 +/− lungs at P3 during the course of HOX. Haematoxylin and eosin staining of Fgf10 +/− lungs (n = 4) revealed an abnormal phenotype compared with WT lungs (n = 4), with enlarged alveolar sacs and thinner interalveolar walls ( Figure 1G Fgf10 +/− lungs exhibit impaired morphometry at E18.5 associated with reduced Fgf signalling and epithelial marker expression as well as increased Tgfβ signalling and ECM protein expression
We examined the presence of potential lung defects in E18.5 Fgf10 +/− embryos. We also used previously described Fgf10
LacZ/− hypomorphic mutants [20] . These two lines exhibit 50% and 20% Fgf10 expression compared with WT lungs, respectively. Figure 2A LacZ/− hypomorphic lungs mostly showed increased septal wall thickness with moderately, but significantly, increased MLI. The reason for this difference is unclear. So far, our results have shown that at P3, there is no obvious difference between Fgf10 +/− and Fgf10 +/+ in NOX. However, at E18.5, morphometric analyses revealed differences between the two genotypes. The cellular and molecular mechanisms involved in this apparent recovery from E18.5 to P3 are so far unknown. In order to further characterize the nature of the lung morphological differences between the three conditions, we isolated RNA from WT (n = 3), Fgf10 +/− (n = 7), and Fgf10 LacZ/− hypomorphic (n = 3) E18.5 lungs and carried out transcriptome analyses. Our approach using two distinct types of Fgf10 mutants exhibiting different Fgf10 levels allowed us to identify the top 70 mRNAs (selected based on p value) which were differentially regulated between Fgf10
LacZ/− hypomorph and WT lungs, and then to compare the expression of these genes between Fgf10 +/− and WT lungs. The heatmap in Figure 2C , a (see supplementary material online, Figure S2 for greater magnification) shows that these mRNAs were indeed also similarly decreased or increased in Fgf10 +/− versus WT lungs. The graph in Figure 2C , b summarizes the different cellular compartments and biological processes that are potentially affected based on the known function of the identified genes. Interestingly, the expected epithelial defects of Fgf10 deficiency could, in part, be caused by the dysregulated expression of epithelium-specific genes, such as lysophosphatidylcholine acyltransferase 1 (Lpcat1), phosphatidylinositol-4-phosphate-5-kinase, type I, alpha (Pip5k1a), G-protein-coupled receptor 30 (Gpr30), calpain 6 (Capn6), and pleiotrophin (Ptn). In particular, Lpcat1 deficiency has been associated with neonatal death due to surfactant defects [23] , while Ptn promotes the proliferation of alveolar epithelial type II (AECII) cells and prevents their differentiation into AECI [24] . In addition to those implicated in epithelial defects, we also identified changes in transcripts expressed in muscle, the immune system, +/− and WT lungs at E18.5 ( Figure 2D , a, b). We found that the mRNA levels of Fgf10, Fgfr2b, and Bmp4, the latter a downstream target of Fgf10 in the epithelium, were decreased (all statistically significant). An overall trend of decreasing expression was also observed for other epithelial marker mRNAs. Epcam levels were significantly reduced, supporting the notion that alterations occur in the epithelial compartment, which is the main cellular target of Fgf10 signalling. As Fgf10 and Tgfβ1 play opposite roles during lung development, we also investigated the expression of genes involved in Tgfβ signalling and the associated ECM ( Figure 2D, c, d ). We found significantly increased Smad3, Smad7, and IL-1b levels, but no changes for Tgfb1 and Tgfb3. Additionally, mRNA levels for different types of collagen (Col1a1, Col1a2, Col3a1, and Col5a2) showed trends to increase. The increase in Tgfβ signalling was confirmed by IF using phospho-Smad3 antibodies (see supplementary material, Figure S3 ).
Characterization of the response to oxygen injury in AECII cells isolated from the lungs of WT and Fgf10 +/− mice In order to identify the significant genes/pathways differentially affected in AECII cells by HOX versus NOX between Fgf10 +/− and WT, we isolated AECII cells from Fgf10 +/− and WT P3 lungs in NOX and HOX conditions and compared their transcriptomes (see supplementary material online, Figure S4 ). In particular, we carried out an interaction 'HOX × genotype' analysis ( Figure 3) . The volcano plot identified a set of genes that are either up-or down-regulated ( Figure 3A) . Interestingly, the majority of differences between the genotypes occurred in the down-regulated genes.
The top 100 regulated genes according to their p values are represented in the corresponding heatmaps ( Figure 3B , a, b; see supplementary material online, Figure S5 for greater magnification). We found a gene set (located in the lower part of the array) whose expression was not drastically changed in HOX between the two genotypes ( Figure 3B, a) , but was differentially regulated in NOX conditions ( Figure 3B, b) . Furthermore, another gene set down-regulated in HOX (located in the top part of the array) was up-regulated in NOX conditions. KEGG analysis revealed that the processes altered were almost all linked to the immune system and were down-regulated in mutant AECII cells ( Figure 3C ). These processes were systemic lupus erythematous, Staphylococcus aureus infection, antigen presentation, graft versus host disease, and autoimmune thyroid disease, amongst others. In order to assess the differentiation status of the isolated AECII cells in Fgf10 +/− versus WT lungs, we analysed the expression of the previously reported signatures for AECII and AECI [25] in the arrays generated from these cells in both NOX ( Figure 3D ) and HOX conditions ( Figure 3E ) (see supplementary material online, Figure S6 for greater magnification). In both conditions, we found a decrease in the AECII signature, with a corresponding increase in the AECI signature. Figure 3F , comparing differential expression between genotypes in HOX versus NOX, confirms the differential clustering of the signatures for AECI and AECII.
Fgf10
+/− lungs in the context of HOX exhibit decreased surfactant expression Using western blotting (whole lung homogenates, n = 4 for WT and n = 3 for Fgf10 +/− lungs at P3; Figure 4A , a, b), we quantified the protein expression of Fgf10, Fgfr2 (using an antibody which does not discriminate between the Fgfr2b versus the Fgfr2c isoform), and mature Sftpc and Sftpb. We noted significantly reduced expression of all of these markers in Fgf10 +/− versus WT ( Figure 4A , a-f). A decrease in Sftpb expression was also supported by immunofluorescence ( Figure 4B, a, b) . Figure 3F) . Interestingly, the prevalence of EpiSPCs was not different between Fgf10 +/− and WT lungs ( Figure 4C, d) . Following hyperoxic injury, the ratio of epithelial cells (Epcam+/whole lung) in Fgf10 +/− versus WT was no longer significant ( Figure 4C, e) . However, the quantitative imbalance in the AECI ratio in Fgf10 +/− versus WT remained ( Figure 4C, f) , while the AECII ratio in Fgf10 +/− versus WT was no longer significant ( Figure 4C, g ). As for NOX, no difference was observed in the ratio of EpiSPCs in Fgf10 +/− versus WT ( Figure 4C, h) . Next, we assessed cell proliferation using IF for Ki67 ( Figure 4D ). In this analysis, we did not discriminate between epithelium and mesenchyme. In NOX, we observed a trend towards increased proliferation in Fgf10 +/− versus WT lungs ( Figure 4D, a-c) . In HOX, a significant increase in Ki67-positive cells was observed in Postnatal attenuation of Fgfr2b ligands in NOX, during the saccular/alveolar stage of lung development, does not cause lung structural defects or lethality
As no congenital mutation in the FGF10 gene in patients with BPD has been reported so far, it is likely that in BPD babies, the initial stages of lung development occur in the presence of normal levels of FGF10. To mimic this situation in a mouse model, we used a previously reported dominant negative soluble Fgfr2b expres Fgfr2b signalling [15] [16] [17] [18] [19] 26] . Using this approach, we disrupted Fgfr2b signalling (mediated by Fgf1, −3, −7, and −10; see Figure 1A ) in the postnatal lung during the saccular and the beginning of the alveolar stages, between P0 and P8 ( Figure 5A-D) . In NOX, we observed no lethality ( Figure 5B ) and no structural defects ( Figure 5C , D) between double-transgenic experimental lungs (DTG) and single-transgenic control lungs (STG). Similar results were observed upon exposure to doxycycline for a longer time period, from P0 to P105 (data not shown).
Postnatal attenuation of Fgfr2b ligands in HOX, during the saccular/alveolar stage of lung development, leads to significant lethality In order to investigate the impact of Fgfr2b ligands attenuation during neonatal hyperoxia lung injury, we exposed two litters fed with doxycyclin through the mother (including littermate controls; total 15 pups) to NOX and HOX (P0-P8). In contrast to NOX, HOX induced lethality in 50% of the +/− neonatal mice, this lethality started 1 day later (see Figure 1F ) and the lethality at P8 was less (100% versus 50% dead in Fgf10 +/− versus DTG, respectively). Morphometry at P3 (Figure 5G , H) showed increased MLI (+19.3%, p = 0.029) in the DTG compared with the STG group control. This increase, compared with the Fgf10 +/− versus WT in HOX ( Figure 1H, a) (+68.2%, p = 0.001), supports our conclusion that in HOX, DTG lungs exhibit a less severe phenotype than do Fgf10 +/− lungs. The lungs of Fgf10 +/− mice at P3 in HOX had quantitative defects (increased AECI, decreased AECII) as well as impaired AECII differentiation (reduced AECII signature, increased AECI signature) associated with reduced Sftpc expression, so we also carried out western blotting for Sftpc, as well as FACS analysis, to assess the total number of epithelial cells (using Epcam), AECI (Pdpn-positive), and AECII (Sftpc-positive) in DTG and DTG and STG mice for Epcam, AECI or AECII cell fractions ( Figure 6D ).
Discussion
Fgf10 maintains undifferentiated the Sox9/Id2-positive cells present in the distal lung epithelium [27, 28] . These cells are multipotent epithelial progenitor cells. Lineage tracing using Id2-CreERT2 showed that they give rise to both bronchiolar and alveolar progenitors. Based on single cell transcriptome studies of the developing epithelium, the alveolar progenitors represent a population of 'bipotent progenitor cells'. These bipotent cells differentiate into either The bipotent progenitor cells exhibit both signatures [25] . Our results suggest that Fgf10 may play a key role in directing the differentiation of the bipotent progenitor cells towards the AECII lineage. This conclusion is based on the observation that while the epithelial compartment is decreased in Fgf10 +/− lungs, the ratio of AECII cells (to Epcam-positive cells) is also decreased, while that of AECI cells is increased. Interestingly, Fgf10 hypomorphic lungs, exhibiting around 20% of the WT Fgf10 mRNA level, also show a pronounced defect in AECII cells [20] , supporting a role for Fgf10 in the ontogeny of the AECII lineage. The role, in this differentiation process, of the other Fgfr2b ligands abundantly expressed in the lung (Fgf1 and Fgf7) is unclear and will also need to be addressed. The observation that surfactant production, which is AECII's primary function, is compromised in Fgf10 +/− in HOX supports our conclusion that AECII cells from Fgf10 +/− lungs are deficient. Interestingly, the AECII cells of Fgf10
lungs are still capable of producing enough surfactant to allow normal lung function in NOX. However, following HOX, these cells are prematurely lost due to built-in developmental (differentiation) defects that remain to be defined. The observed increase in epithelial proliferation and the FACS data from Fgf10 +/− versus WT lungs upon HOX injury appear to indicate an attempt to replenish the failing AECII pool. This newly formed AECII cell pool arising from either AECII stem cells [29] or other still unidentified sources is apparently not able to compensate for the loss of surfactant protein b and c production. Western blotting analysis at P3 clearly showed a significant decrease in Sftpc and Sftpb expression ( Figure 4A, a, b) . Decreased surfactant expression is likely a major contributor to the lethal phenotype upon injury. Impaired surfactant production following hyperoxia exposure in adult mice upon Fgfr2b ligand blocking has been reported previously [30] . In neonatal lung injury, the present results support the role of Fgfr2b ligands in the repair process of the AECII cells, and the associated surfactant expression.
Genome-wide association studies did not associate single-nucleotide polymorphisms in the FGF10 gene with BPD [31] . Constitutive mutations in FGF10 therefore appear to be rare, or non-existent, in BPD patients. However, the reduction in FGF10, which is linked to inflammation, may be associated with some of the clinical manifestations.
Our transcriptome results suggest that differences exist in the immune status of AECII cells in Fgf10 +/− versus WT lungs. The role of FGF signalling in controlling inflammation is still controversial. In primary cultures of human airway epithelial cells, FGF7 decreases transcript abundance for many interferon-induced genes, which may attenuate the response of epithelial cells to inflammatory mediators [32] (see ref 33 for a review of the role of Fgf7 in the lung). Short-term overexpression of Fgf7 in vivo, 3 days prior to acute lung injury, is protective. However, Fgf7 exposure for 7 days or longer increases lung inflammation and injury, suggesting differential cytoprotective versus inflammatory effects of Fgf7, dependent on the duration of growth factor treatment [34] . To date, such negative inflammatory effects have not been reported for Fgf10. In the future, precise analysis of epithelial gene expression will be critical for a better understanding of the biological responses triggered by Fgf10 versus Fgf7. Fgf10 increases the recruitment of T-regulatory cells in the context of bleomycin injury [35] and mobilizes lung-resident mesenchymal stem cells and protects against acute lung injury [36] . Whether these effects are triggered by Fgf10-mediated epithelial signals or by Fgf10 acting on these inflammatory/stem cells remains to be elucidated.
Our results are also of interest regarding ALSG (aplasia of lacrimal and salivary glands) or LADD (lacrimo-auriculo-dento-digital syndrome) patients (exhibiting FGF10 or FGFR2b mutations). While these patients initially appear to have normal lung function, they develop chronic obstructive pulmonary disease [37] . This is likely associated with deficient repair of the epithelium upon injury. It still remains to be investigated whether this is due to developmental defects in the epithelial progenitors and/or insufficient postnatal FGF10 levels that compromise epithelial maintenance. One aspect is clear; these patients will likely be more prone to lung disease than the normal population. At a minimum, prophylactic preventive measures should be considered for these 'at-risk' patients. Figure S1 . Validation of the HOX injury model to trigger hypoalveologenesis Figure 3B , a, b Figure S6 . Greater magnification of the graphs shown in Figure 3D , E Figure S7 . Impact of HOX versus NOX on the epithelium and mesenchyme of Fgf10 +/− and WT lungs at P3 Table S1 . Primers used for RT-qPCR Table S2 . Antibodies used for western blotting To view these ar cles, and more, please visit: www.thejournalofpathology.com
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